A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic‐based cohort of patients with diabetes onset over 50 years

Publisher Website
Google Scholar
Abstract
Aims To assess if a clinically orientated approach improves screening for latent autoimmune diabetes in adults (LADA) in patients developing diabetes over age 50. Methods From a clinic‐based cohort of 3327 patients with Type 2 DM diagnosed over age 50 we recruited those with at least one feature suggestive of insulin deficiency: (i) fasting blood glucose ≥ 15 mmol/l and/or HbA1c ≥ 10% in spite of adequate compliance to diet and treatment; (ii) decreasing body weight ≥ 10% in the previous 3 months in spite of constant diet; (iii) BMI < 25 mg/kg2. A control group of 240 patients not presenting any of the previous criteria was randomly selected from the out‐patient clinic. Results We identified 220 (6.6%) patients, of whom 70 were positive for glutamic acid decarboxylase antibodies (GADA) and/or islet cell antibodies (ICA), giving a prevalence of LADA of 31.8% (95% CI 25.7–38.4). In contrast, no patient randomly selected from the remaining cohort had marker positivities. With respect to patients negative for both ICA and GADA, those who were positive had lower C‐peptide values (0.53 ± 0.51 vs. 0.88 ± 0.42 nmol/l, P < 0.001); the lowest levels were found in patients in whom both antibodies were positive. In linear regression analysis, variables independently associated with fasting C‐peptide were GADA (β = −0.25, P < 0.001), ICA (β = −0.15, P = 0.04), BMI (β = 0.03, P < 0.001) and duration of diabetes (β = −0.02, P < 0.001). Conclusion This study shows that: (i) a clinically orientated approach increases the efficiency of a screening programme for LADA, so that one in three screened patients are classified correctly; (ii) ICA and GADA positivity were negatively associated with residual β‐cell function, independent of BMI and duration of the disease; (iii) positivity for both ICA and GADA identifies patients with the lowest residual β‐cell function.